Matt Hoffman

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with David Vossler, MD.

The current perspective on the care of patients and the anticipated developments of the future are detailed in part 3 of this special 3-part multimedia series on the evolution of migraine care.

The medical director manager of neuroscience at Genentech discussed the swath of data presented on the humanized anti-CD20 monoclonal antibody at MS Virtual.

Early intensive treatment was more effective in controlling disability progression over time compared with an escalation therapy approach.

The positive top-line data from Study 3 revealed that children with Dravet syndrome experienced more than a 60% greater reduction in mean monthly convulsive seizures compared to placebo.

The director of the VA Southwest Parkinson’s Disease Research, Education, and Clinical Centers spoke to the importance of patient-focused interventions in PD.

Atara Biotherapeutics’ allogeneic EBV-targeted T-cell therapy, ATA188, is well-tolerated in phase 1, with a dose identified for the randomized placebo-controlled portion of the study.

Marinus Pharmaceuticals’ positive allosteric GABAA receptor modulator ganaxolone was associated with significant median reductions in 28-day major motor seizure frequency compared to placebo.

A pair of datasets from the phase 3b CASTING study of ocrelizumab (Ocrevus; Genentech) suggest that patients treated with the agent experienced high rates of no evidence of disease activity status regardless of prior DMT exposure.

The ongoing fight to add to the epidemiologic understanding of migraine is explored in part 2 of this special 3-part multimedia series on the evolution of migraine care.

The director of the VA Southwest Parkinson’s Disease Research, Education, and Clinical Centers offered background the inspiration for the study and why loneliness should be addressed in these patients.

The recently approved apomorphine sublingual film (Kynmobi; Sunovion) maintained efficacy over the long-term, with at least 74% of patients experiencing full ON within 30 minutes post-dose at each time point.

Data show that higher CSF tau levels at diagnosis correlated with worse disability independent of age, though no such associations were identified with amyloid-beta.

The COMT inhibitor, which was approved in April 2020, may be a worthwhile option as a first-line adjunctive treatment for those with Parkinson disease with motor fluctuations.

Three-year data from a phase 1 study of Voyager Therapeutics’ VY-AADC01 suggest it is safe and offers potential benefits for patients with Parkinson disease.

Results from a phase 2 pilot study of nabilone in Parkinson disease suggest that the synthetic cannabinoid might hold therapeutic potential for nonmotor symptoms.

Mind Moments, a podcast from NeurologyLive, brings you an exclusive interview with Stewart Tepper, MD, in part 1 of this special 3-part multimedia series on the evolution of migraine care.

The investigator at the Healey & AMG Center for ALS at Massachusetts General Hospital spoke to the CENTAUR open-label extension and AMX0035’s development.

The Project ALS-funded oral MAP4 kinase inhibitor has been described in the literature as an exceptionally potent, metabolically stable, and blood-brain barrier-penetrant compound.

The chief scientific officer at the Parkinson’s Foundation shares his perspective on the current state of Parkinson research and development amid the challenges of the pandemic.

Multidisciplinary teams who had the pocket card available had shorter times to rescue therapy initiation and similar rates of adequate dosing.

Findings suggest that compared with isolated cases, both earlier age at initial episode and a higher prevalence of personal and family history of migraine are linked to TGA recurrence.

Data from the CENTAUR trial showed that the monthly rate of decline measured by ALSFR-S was 0.42 points slower for patients treated with the combination agent AMX0035.

The findings support the integration of sleep assessments into routine developmental screenings in school and primary care settings.

Pooled data from 2 clinical trials of the H3-receptor antagonist/inverse agonist show it improved cataplexy and excessive daytime sleepiness in patients with narcolepsy who were most hampered by symptoms.

After wearing the noninvasive device, 62% of TETRAS-rated patients and 68% of BF-ADL-rated patients whose tremors were rated as "severe" or "moderate" improved to "mild" or "slight" scores.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Rajesh Pahwa, MD.

Multiple abstracts at SLEEP 2020 show CBT-I’s success in aiding women with insomnia, including those going through pregnancy, and those who are veterans both with and without PTSD.

Howard Fillit, MD, founding executive director and chief science officer of the Alzheimer's Drug Discovery Foundation and clinical professor of geriatric medicine and palliative care, medicine, and neuroscience at Mount Sinai School of Medicine, detailed the role telemedicine plays in treating Alzheimer disease.

The first-in-class CH24H inhibitor was associated with a reduction in seizures and seizure frequency in an early analysis of the phase 2 ELEKTRA study, with plans to initiate the move to phase 3 in Dravet syndrome.